Neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer (BRPC).

被引：1
|
作者：
Tran, Nguyen H.
Sahai, Vaibhav
Griffith, Kent A.
Nathan, Hari
Kaza, Ravi
Cuneo, Kyle Clifford
Sonnenday, Christopher J.
Cho, Clifford
Lawrence, Theodore Steven
Zalupski, Mark
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Hlth Syst, Ann Arbor, MI USA
[3] Univ Massachusetts, Mem Med Ctr, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.381
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
381
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Is Preoperative Chemoradiation Necessary for Borderline Resectable Pancreatic Cancer (BRPC)?: Clinical and Surgical Outcomes Associated with Neoadjuvant FOLFIRINOX Alone in BRPC
    Kim, S. S.
    Ko, A. H.
    Wang, Z. J.
    Kim, G. E.
    Corvera, C. U.
    Harris, H. W.
    Kirkwood, K. S.
    Hirose, R.
    Tempero, M. A.
    Nakakura, E. K.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S165 - S165
  • [2] Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer
    Waugh, Evelyn
    Glinka, Juan
    Breadner, Daniel
    Liu, Rachel
    Tang, Ephraim
    Allen, Laura
    Welch, Stephen
    Leslie, Ken
    Skaro, Anton
    ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2024, 28 (02) : 229 - 237
  • [3] Toxicity associated with neoadjuvant therapy for borderline resectable pancreatic cancer (BRPC).
    Beg, M. S.
    Olowokure, O. O.
    Ali, S.
    Ahmad, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer
    Kharofa, Jordan
    Tsai, Susan
    Kelly, Tracy
    Wood, Clint
    George, Ben
    Ritch, Paul
    Wiebe, Lauren
    Christians, Kathleen
    Evans, Douglas B.
    Erickson, Beth
    RADIOTHERAPY AND ONCOLOGY, 2014, 113 (01) : 41 - 46
  • [5] Is neoadjuvant chemoradiation important in borderline resectable pancreatic cancer (BRPC)? Clinical and surgical outcomes associated with preoperative FOLFIRINOX alone in BRPC.
    Kim, Sunhee S.
    Nakakura, Eric K.
    Wang, Zhen J.
    Kim, Grace E.
    Corvera, Carlos U.
    Harris, Hobart W.
    Kirkwood, Kimberly S.
    Hirose, Ryutaro
    Tempero, Margaret A.
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)''
    Wei, Lee-Jen
    McCaw, Zachary R.
    Tian, Lu
    Kim, Dae Hyun
    ANNALS OF SURGERY, 2019, 270 (02) : E48 - E50
  • [7] Neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer
    Shahda, Safi
    House, Michael G.
    Schmidt, C. Max
    Nakeeb, Attila
    Sehdev, Amikar
    Lin, Jingmei
    Cramer, Harvey M.
    Tong, Yan
    Flynn, Janet R.
    Zyromski, Nicholas J.
    O'Neil, Bert H.
    CANCER RESEARCH, 2016, 76
  • [8] Efficacy of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma
    Kang, J.
    Kim, K-P.
    Yoo, C.
    Lee, J-L.
    Ryoo, B-Y.
    Chang, H-M.
    Lee, S. S.
    Park, D. H.
    Song, T. J.
    Seo, D. W.
    Lee, S. K.
    Kim, M-H.
    Hwang, D. W.
    Song, K. B.
    Lee, J. H.
    Kim, S. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer
    Cho, In Rae
    Chung, Moon Jae
    Bang, Seungmin
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    Seong, Jinsil
    Hwang, Ho Kyoung
    Kang, Chang Moo
    Lee, Woo Jung
    Park, Jeong Youp
    PANCREATOLOGY, 2013, 13 (05) : 539 - 543
  • [10] Clinical Outcomes of the Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine Versus FOLFIRINOX
    Choi, Y. J.
    Kang, J. S.
    Byun, Y.
    Kim, H. S.
    Han, Y.
    Kim, H.
    Kim, E.
    Kwon, W.
    Jang, J. Y.
    PANCREAS, 2019, 48 (10) : 1414 - 1414
12345